What is the latest price of osimertinib in 2024?

Osimertinib is a third-generation epidermal growth factor receptor tyrosine kinase inhibitor (TKI) that is widely used to treat metastatic EGFR T790M mutation-positive non-small cell lung cancer (NSCLC). The drug is already on the market in China and is included in medical insurance. Patients can consult and purchase it at local hospital pharmacies. In the domestic market, the price of osimertinib is approximately 4000-7000 yuan.

Laos and Bangladesh have officially marketed generic drugs for patients to choose from. The ingredients of these generic drugs are basically the same as those of the original drugs. The latest price is about a few hundred yuan, and the most expensive may reach one or two thousand yuan.

Osimertinib is approved as a first-line treatment option for patients withEGFR T790M mutation-positiveNSCLC. The T790M mutation is an acquired resistance mechanism that is widespread in NSCLC patients receiving first-generation TKI treatment. However, first- and second-generation TKIs are unable to inhibit the T790M mutation at clinically relevant concentrations. Osimertinib selectively inhibits mutant EGFR, including TKI sensitive mutations L858R and exon 19 deletions, and acquired resistance mutation T790M. In a clinical trial comparing osimertinib to platinum-based dual chemotherapy in patients with NSCLC whose T790M mutation had progressed, median progression-free survival was significantly longer in the osimertinib group. Moreover, osimertinib has a good safety profile compared with platinum-based doublet chemotherapy.

Common adverse events of osimertinib include diarrhea, rash, dry skin and paronychia; however, because it does not affect wild-type EGFR, it is different from other TKIsIn comparison, the frequency and severity of these side effects appear to be lower. Serious but rare adverse events include pneumonia, interstitial lung disease-like events, QT interval prolongation and reduced ejection fraction.

It is worth noting that osimertinib has the special ability to distribute more easily into brain tissue than other TKIs, which makes it potentially useful in the treatment and /or prevention of central nervous system metastasis.